153 results on '"Carcinoma, Ductal, Breast radiotherapy"'
Search Results
2. Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
- Author
-
Mulliez T and De Ridder M
- Subjects
- Humans, Female, Breast pathology, Radiotherapy, Adjuvant, Mastectomy, Segmental, Neoplasm Recurrence, Local pathology, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery, Carcinoma, Intraductal, Noninfiltrating pathology, Breast Neoplasms radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma in Situ
- Published
- 2023
- Full Text
- View/download PDF
3. Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
- Author
-
Chua BH, Link EK, Kunkler IH, and Olivotto IA
- Subjects
- Humans, Female, Breast pathology, Mastectomy, Segmental, Neoplasm Recurrence, Local pathology, Radiotherapy, Adjuvant, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery, Carcinoma, Intraductal, Noninfiltrating pathology, Breast Neoplasms radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma in Situ
- Published
- 2023
- Full Text
- View/download PDF
4. Breast radiotherapy for ductal carcinoma in situ: could less be more?
- Author
-
Coles CE, Chatterjee S, Jagsi R, and Kirby AM
- Subjects
- Breast, Female, Humans, Mastectomy, Segmental, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery
- Published
- 2022
- Full Text
- View/download PDF
5. Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS).
- Author
-
Rossi AJ, Verbus EA, Horst K, De Martini W, Allison K, Hernandez JM, and Wapnir IL
- Subjects
- Female, Humans, Mastectomy, Segmental, Neoadjuvant Therapy, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating pathology, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery
- Published
- 2022
- Full Text
- View/download PDF
6. No Treatment Versus Partial Mastectomy Plus Radiation for Ductal Carcinoma In Situ.
- Author
-
Sun SX, Suk R, Kuerer HM, Cantor SB, Raber BM, and Deshmukh AA
- Subjects
- Female, Humans, Mastectomy, Mastectomy, Segmental, Neoplasm Recurrence, Local, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery
- Published
- 2022
- Full Text
- View/download PDF
7. Breast Irradiation in Ductal Carcinoma In Situ.
- Author
-
Chua BH
- Subjects
- Breast, Female, Humans, Mastectomy, Segmental, Neoplasm Recurrence, Local surgery, Treatment Outcome, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery
- Abstract
There is strong and consistent evidence that whole breast irradiation after breast conserving surgery significantly decreases the risk of ipsilateral breast events, in situ or invasive, underpinning its established role in patients with ductal carcinoma in situ (DCIS). Pending publication of the full results of BIG 3-07/TROG 07.01 randomised trial, addition of tumour bed boost to whole breast irradiation is recommended in the presence of adverse clinical-pathologic features, and the use of moderately hypofractionated whole breast dose-fractionation schedules is supported. As published data supporting the use of adjuvant partial breast irradiation in patients with low-risk DCIS are limited, its off-study application should be limited to low-risk patients defined by international and national guidelines. Finally, low-risk patients may not derive clinically meaningful benefits from radiation therapy and research on molecular profiling is ongoing to improve prognostic precision and guide safe omission of radiation therapy after breast conserving surgery., (Celsius.)
- Published
- 2021
- Full Text
- View/download PDF
8. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
- Author
-
Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, Stenbygaard L, Mjaaland I, Schreiber A, Kasti UM, and Overgaard J
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma surgery, Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Cardiotoxicity etiology, Cicatrix etiology, Edema etiology, Female, Humans, Lymph Nodes pathology, Mastectomy, Segmental, Middle Aged, Pain etiology, Patient Satisfaction, Pigmentation Disorders etiology, Radiation Pneumonitis etiology, Radiotherapy, Adjuvant adverse effects, Radiotherapy, Adjuvant methods, Survival Rate, Telangiectasis etiology, Adenocarcinoma radiotherapy, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Neoplasm Recurrence, Local pathology, Radiation Dose Hypofractionation
- Abstract
Purpose: Given the poor results using hypofractionated radiotherapy for early breast cancer, a dose of 50 Gy in 25 fractions (fr) has been the standard regimen used by the Danish Breast Cancer Group (DBCG) since 1982. Results from more recent trials have stimulated a renewed interest in hypofractionation, and the noninferiority DBCG HYPO trial (ClincalTrials.gov identifier: NCT00909818) was designed to determine whether a dose of 40 Gy in 15 fr does not increase the occurrence of breast induration at 3 years compared with a dose of 50 Gy in 25 fr., Patients and Methods: One thousand eight hundred eighty-two patients > 40 years of age who underwent breast-conserving surgery for node-negative breast cancer or ductal carcinoma in situ (DCIS) were randomly assigned to radiotherapy at a dose of either 50 Gy in 25 fr or 40 Gy in 15 fr. The primary end point was 3-year grade 2-3 breast induration assuming noninferiority regarding locoregional recurrence., Results: A total of 1,854 consenting patients (50 Gy, n = 937; 40 Gy, n = 917) were enrolled from 2009-2014 from eight centers. There were 1,608 patients with adenocarcinoma and 246 patients with DCIS. The 3-year rates of induration were 11.8% (95% CI, 9.7% to 14.1%) in the 50-Gy group and 9.0% (95% CI, 7.2% to 11.1%) in the 40-Gy group (risk difference, -2.7%; 95% CI, -5.6% to 0.2%; P = .07). Systemic therapies and radiotherapy boost did not increase the risk of induration. Telangiectasia, dyspigmentation, scar appearance, edema, and pain were detected at low rates, and cosmetic outcome and patient satisfaction with breast appearance were high with either no difference or better outcome in the 40-Gy cohort compared with the 50-Gy cohort. The 9-year risk of locoregional recurrence was 3.3% (95% CI, 2.0% to 5.0%) in the 50-Gy group and 3.0% (95% CI, 1.9% to 4.5%) in the 40-Gy group (risk difference, -0.3%; 95% CI, -2.3% to 1.7%). The 9-year overall survival was 93.4% (95% CI, 91.1% to 95.1%) in the 50-Gy group and 93.4% (95% CI, 91.0% to 95.2%) in the 40-Gy group. The occurrence of radiation-associated cardiac and lung disease was rare and not influenced by the fractionation regimen., Conclusion: Moderately hypofractionated breast irradiation of node-negative breast cancer or DCIS did not result in more breast induration compared with standard fractionated therapy. Other normal tissue effects were minimal, with similar or less frequent rates in the 40-Gy group. The 9-year locoregional recurrence risk was low., Competing Interests: The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (B.V.O.) had full access to all study data and had final responsibility for the decision to submit for publication. The views expressed in this article are those of the authors.
- Published
- 2020
- Full Text
- View/download PDF
9. International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast.
- Author
-
Olivotto IA, Link E, Phillips C, Whelan TJ, Bryant G, Kunkler IH, Westenberg AH, Purohit K, Ahern V, Graham PH, Akra M, McArdle O, Ludbrook JJ, Harvey JA, Maduro JH, Kirkove C, Gruber G, Martin JD, Campbell ID, Delaney GP, and Chua BH
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Dose Fractionation, Radiation, Female, Humans, Mastectomy, Segmental standards, Middle Aged, Randomized Controlled Trials as Topic, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ radiotherapy, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Mastectomy, Segmental methods
- Abstract
Purpose: To assess the cosmetic impact of breast conserving surgery (BCS), whole breast irradiation (WBI) fractionation and tumour bed boost (TBB) use in a phase III trial for women with ductal carcinoma in situ (DCIS) of the breast., Materials and Methods: Baseline and 3-year cosmesis were assessed using the European Organization for Research and Treatment of Cancer (EORTC) Cosmetic Rating System and digital images in a randomised trial of non-low risk DCIS treated with postoperative WBI +/- TBB. Baseline cosmesis was assessed for four geographic clusters of treating centres. Cosmetic failure was a global score of fair or poor. Cosmetic deterioration was a score change from excellent or good at baseline to fair or poor at three years. Odds ratios for cosmetic deterioration by WBI dose-fractionation and TBB use were calculated for both scoring systems., Results: 1608 women were enrolled from 11 countries between 2007 and 2014. 85-90% had excellent or good baseline cosmesis independent of geography or assessment method. TBB (16 Gy in 8 fractions) was associated with a >2-fold risk of cosmetic deterioration (p < 0.001). Hypofractionated WBI (42.5 Gy in 16 fractions) achieved statistically similar 3-year cosmesis compared to conventional WBI (50 Gy in 25 fractions) (p ≥ 0.18). The adverse impact of a TBB was not significantly associated with WBI fractionation (interaction p ≥ 0.30)., Conclusions: Cosmetic failure from BCS was similar across international jurisdictions. A TBB of 16 Gy increased the rate of cosmetic deterioration. Hypofractionated WBI achieved similar 3-year cosmesis as conventional WBI in women treated with BCS for DCIS., Competing Interests: Declaration of Competing Interest All authors declare no commercial conflicts of interests other than per capita or grant funding to their institutions for patient accrual. The funding bodies had no role in the analysis or reporting of results and did not review or edit the text of the manuscript., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
10. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
- Author
-
Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, and Olivotto IA
- Subjects
- Aged, Australia, Breast Neoplasms surgery, Canada, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Female, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local prevention & control, New Zealand, Prognosis, Survival Rate, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Background: Whole breast irradiation delivered once per day over 3-5 weeks after breast conserving surgery reduces local recurrence with good cosmetic results. Accelerated partial breast irradiation (APBI) delivered over 1 week to the tumour bed was developed to provide a more convenient treatment. In this trial, we investigated if external beam APBI was non-inferior to whole breast irradiation., Methods: We did this multicentre, randomised, non-inferiority trial in 33 cancer centres in Canada, Australia and New Zealand. Women aged 40 years or older with ductal carcinoma in situ or node-negative breast cancer treated by breast conserving surgery were randomly assigned (1:1) to receive either external beam APBI (38·5 Gy in ten fractions delivered twice per day over 5-8 days) or whole breast irradiation (42·5 Gy in 16 fractions once per day over 21 days, or 50 Gy in 25 fractions once per day over 35 days). Patients and clinicans were not masked to treatment assignment. The primary outcome was ipsilateral breast tumour recurrence (IBTR), analysed by intention to treat. The trial was designed on the basis of an expected 5 year IBTR rate of 1·5% in the whole breast irradiation group with 85% power to exclude a 1·5% increase in the APBI group; non-inferiority was shown if the upper limit of the two-sided 90% CI for the IBTR hazard ratio (HR) was less than 2·02. This trial is registered with ClinicalTrials.gov, NCT00282035., Findings: Between Feb 7, 2006, and July 15, 2011, we enrolled 2135 women. 1070 were randomly assigned to receive APBI and 1065 were assigned to receive whole breast irradiation. Six patients in the APBI group withdrew before treatment, four more did not receive radiotherapy, and 16 patients received whole breast irradiation. In the whole breast irradiation group, 16 patients withdrew, and two more did not receive radiotherapy. In the APBI group, a further 14 patients were lost to follow-up and nine patients withdrew during the follow-up period. In the whole breast irradiation group, 20 patients were lost to follow-up and 35 withdrew during follow-up. Median follow-up was 8·6 years (IQR 7·3-9·9). The 8-year cumulative rates of IBTR were 3·0% (95% CI 1·9-4·0) in the APBI group and 2·8% (1·8-3·9) in the whole breast irradiation group. The HR for APBI versus whole breast radiation was 1·27 (90% CI 0·84-1·91). Acute radiation toxicity (grade ≥2, within 3 months of radiotherapy start) occurred less frequently in patients treated with APBI (300 [28%] of 1070 patients) than whole breast irradiation (484 [45%] of 1065 patients, p<0·0001). Late radiation toxicity (grade ≥2, later than 3 months) was more common in patients treated with APBI (346 [32%] of 1070 patients) than whole breast irradiation (142 [13%] of 1065 patients; p<0·0001). Adverse cosmesis (defined as fair or poor) was more common in patients treated with APBI than in those treated by whole breast irradiation at 3 years (absolute difference, 11·3%, 95% CI 7·5-15·0), 5 years (16·5%, 12·5-20·4), and 7 years (17·7%, 12·9-22·3)., Interpretation: External beam APBI was non-inferior to whole breast irradiation in preventing IBTR. Although less acute toxicity was observed, the regimen used was associated with an increase in moderate late toxicity and adverse cosmesis, which might be related to the twice per day treatment. Other approaches, such as treatment once per day, might not adversely affect cosmesis and should be studied., Funding: Canadian Institutes for Health Research and Canadian Breast Cancer Research Alliance., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
11. Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series.
- Author
-
Leonardi MC, Corrao G, Frassoni S, Vingiani A, Dicuonzo S, Lazzeroni M, Fodor C, Morra A, Gerardi MA, Rojas DP, Dell'Acqua V, Marvaso G, Bassi FD, Galimberti VE, Veronesi P, Miglietta E, Cattani F, Zurrida S, Bagnardi V, Viale G, Orecchia R, and Jereczek-Fossa BA
- Subjects
- Adult, Aged, Brachytherapy, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating pathology, Carcinoma, Intraductal, Noninfiltrating surgery, Disease-Free Survival, Female, Humans, Intraoperative Care methods, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local pathology, Survival Rate, Treatment Outcome, United States, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Intraductal, Noninfiltrating radiotherapy
- Abstract
Aims: To report the long-term outcome of a single institution series of pure ductal carcinoma in situ (DCIS) treated with accelerated partial irradiation using intraoperative electrons (IOERT)., Methods: From 2000 to 2010, 180 DCIS patients, treated with quadrantectomy and 21 Gy IOERT, were analyzed in terms of ipsilateral breast recurrences (IBRs) and survival outcomes by stratification in two subgroups. The low-risk group included patients who fulfilled the suitable definition according to American Society of Radiation Oncology (ASTRO) Guidelines (size ≤2.5 cm, grade 1-2 and surgical margins ≥3 mm) (Suitable), while the remaining ones formed the high-risk group (Non-Suitable)., Results: Eighty-four and 96 patients formed the Suitable and Non-Suitable groups, respectively. In the whole population, the cumulative incidence of IBR at 5, 7 and 10 years was 19%, 21%, and 25%, respectively. In the Suitable group, the cumulative incidence of IBR remained constant at 11% throughout the years, while in the Non-Suitable group increased from 26% at 5 years to 36% at 10 years (p < 0.0001). When hormonal positivity and HER2 absence of expression were added to the selection of the Suitable group, the cumulative incidence of IBR dropped and stabilized at 4% at 10 years. None died of breast cancer. In the whole population, 5-year and 10-year overall survival rate was 98% and 96.5%, respectively, without any difference between the two groups., Conclusions: The overall and by group IBR rates were high and stricter criteria are required for acceptable local control for Suitable DCIS. Because of the concerns raised, IOERT should not be used in clinical practice., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
12. Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.
- Author
-
Hamilton SN, Nichol A, Wai E, Gondara L, Velásquez García HA, Speers C, Diocee R, and Truong P
- Subjects
- Adult, Aged, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Proportional Hazards Models, Radiotherapy methods, Radiotherapy Planning, Computer-Assisted, Recurrence, Risk, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Mastectomy methods, Mastectomy, Segmental methods, Neoplasm Recurrence, Local diagnosis
- Abstract
Purpose: The optimal treatment for patients with extensive pure ductal carcinoma in situ (DCIS) ≥4 cm is controversial. This study evaluates local relapse according to type of local therapy: mastectomy, breast-conserving surgery (BCS) alone, and BCS + radiation therapy (RT)., Methods and Materials: Subjects were female patients who received diagnoses of pure DCIS ≥4 cm between 1989 and 2010 and were referred to British Columbia Cancer. Clinicopathologic and treatment characteristics were compared between treatment cohorts. Local relapse (LR) was estimated using competing risk analysis. Multivariable analysis was performed using Cox regression analysis., Results: Patients had the following treatments: 490 mastectomy, 38 BCS alone, and 192 BCS + RT. The 10-year cumulative incidence of LR was 16% after BCS (95% confidence interval [CI], 6-29%), 8% after BCS + RT (95% CI, 4-12%), and 2% after mastectomy (95% CI, 1-4%). On multivariable analysis, estrogen receptor-negative disease (hazard ratio [HR], 3.32; 95% CI, 1.08-10.18; P = .04) and positive margins (HR, 3.55; 95% CI, 1.56-8.05; P = .002) were associated with increased LR. BCS alone (HR, 7.87; 95% CI, 2.82-21.92; P < .0001), BCS + RT + no boost (HR, 3.80; 95% CI, 1.56-9.28; P = .003), and BCS + RT + boost (HR, 5.76; 95% CI, 2.59-12.83; P < .0001) were all associated with a higher risk of relapse relative to mastectomy., Conclusions: Mastectomy remains a standard local treatment option for extensive DCIS, but BCS + RT may also be reasonably considered in selected patients with a careful discussion of the benefits, side effects, and patient preferences., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. To Treat or Not to Treat? A Postmastectomy Question.
- Author
-
Bates JE and Bradley JA
- Subjects
- Breast Neoplasms diagnostic imaging, Carcinoma in Situ diagnostic imaging, Carcinoma, Ductal, Breast diagnostic imaging, Female, Humans, Magnetic Resonance Imaging, Mammaplasty, Mastectomy, Middle Aged, Neoplasms, Multiple Primary diagnostic imaging, Postoperative Period, Radiotherapy, Adjuvant, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Neoplasms, Multiple Primary radiotherapy
- Published
- 2018
- Full Text
- View/download PDF
14. Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ.
- Author
-
Ekatah GE, Turnbull AK, Arthur LM, Thomas J, Dodds C, and Dixon JM
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Margins of Excision, Middle Aged, Neoplasm Recurrence, Local, Survival Rate, Treatment Outcome, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Mastectomy, Segmental
- Abstract
Introduction: Ductal Carcinoma in situ (DCIS) represents 5% of symptomatic and 20-30% of screen detected cancers. Breast conserving surgery (BCS) ± radiotherapy is performed in over 70% of women with DCIS. What constitutes an adequate margin for BCS remains unclear., Methods: A single institution follow up study has been conducted of 466 patients with pure DCIS treated by BCS between 2000 and 2010 of whom 292 received whole breast radiotherapy and 167 did not. Patients were selected for radiotherapy based on perceived risk of in breast tumour recurrence (IBTR). Distance to nearest radial margin was measured; 10 patients had a margin width of <1 mm, 94 had widths of 1-2 mm and 362 had widths of >2 mm. There was no association of margin width and the use of radiotherapy., Results: At a median follow up of 7.2 years there were 44 IBTR (27 DCIS and 17 invasive). There was no evidence that margin widths >2 mm resulted in a lower rate of IBTR than margin widths of 1-2 mm. The actuarial IBTR rates at 5 and 10 years for margins of 1-2 mm were 9.0% (95% CI ± 5.9%) and 9.0% (95% CI ± 5.9%) respectively and for margins of >2 mm were 8.0% (95% CI ± 3.9%) and 13.0% (95% CI ± 3.9%) respectively. Odds Ratio for IBTR 1-2 mm vs >2 mm was 0.839 (95% CI 0.392-1.827) p = 0.846. In a multivariate analysis only DCIS size predicted for IBTR (HR 2.73 p < 0.0001)., Conclusion: 1 mm appears a sufficient margin width for BCS in DCIS irrespective of whether patients receive radiotherapy., (Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
15. Intraoperative radiation therapy for breast cancer: a patient's view.
- Author
-
Bernstein M
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
16. Partial breast irradiation and the GEC-ESTRO trial.
- Author
-
Vaidya JS, Bulsara M, Wenz F, Tobias JS, Joseph D, and Baum M
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
17. Partial breast irradiation and the GEC-ESTRO trial.
- Author
-
Vicini F, Shah C, Arthur D, Khan A, Wazer D, and Keisch M
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
18. Partial breast irradiation and the GEC-ESTRO trial - Authors' reply.
- Author
-
Strnad V, Uter W, and Polgár C
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
19. Lymphedema Precautions: Time to Abandon Old Practices?
- Author
-
Ahn S and Port ER
- Subjects
- Biopsy, Large-Core Needle, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Carcinoma in Situ diagnostic imaging, Carcinoma in Situ pathology, Carcinoma, Ductal, Breast diagnostic imaging, Carcinoma, Ductal, Breast pathology, Female, Humans, Mammography, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Upper Extremity, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Lymphedema etiology, Lymphedema prevention & control
- Abstract
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.A 46-year-old premenopausal woman with a body mass index of 21 was found on screening mammography to have a new, approximately 1-cm spiculated mass with associated calcifications in the upper outer quadrant of the left breast. Stereotactic core biopsy showed a focus of invasive duct carcinoma, strongly positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2, with associated ductal carcinoma in situ. Clinical examination revealed no palpable mass or axillary lymphadenopathy. She underwent a left lumpectomy with seed localization and sentinel lymph node biopsy. Final pathology revealed an 8-mm well-differentiated invasive carcinoma without lymphovascular invasion and intermediate grade ductal carcinoma in situ. The margins were clear, and three sentinel lymph nodes were negative for metastasis. The 21-gene recurrence score was 10, suggesting a 7% risk of 10-year distant recurrence with adjuvant endocrine treatment. After the completion of adjuvant radiotherapy (42.50 Gy in 16 fractions to the breast), the patient has returned for a follow-up visit. She is a professional violinist and would like to know what she can do to prevent lymphedema on her upcoming flight to Vienna., (© 2015 by American Society of Clinical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
20. [Accelerated partial breast irradiation using interstitial multicatheter brachytherapy: A valid treatment option for breast cancer patients with a low-risk profile?].
- Author
-
Krug D
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
21. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.
- Author
-
Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Wendt TG, Fietkau R, Hindemith M, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Malzer M, Uter W, and Polgár C
- Subjects
- Adult, Aged, Breast Neoplasms surgery, Breast Neoplasms therapy, Carcinoma in Situ surgery, Carcinoma in Situ therapy, Carcinoma, Ductal, Breast surgery, Carcinoma, Ductal, Breast therapy, Catheters, Indwelling, Combined Modality Therapy, Female, Humans, Mastectomy, Segmental methods, Middle Aged, Radiotherapy Dosage, Treatment Outcome, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Background: In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compared with whole-breast irradiation. Here, we present 5-year follow-up results., Methods: We did a phase 3, randomised, non-inferiority trial at 16 hospitals and medical centres in seven European countries. 1184 patients with low-risk invasive and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either whole-breast irradiation or APBI using multicatheter brachytherapy. The primary endpoint was local recurrence. Analysis was done according to treatment received. This trial is registered with ClinicalTrials.gov, number NCT00402519., Findings: Between April 20, 2004, and July 30, 2009, 551 patients had whole-breast irradiation with tumour-bed boost and 633 patients received APBI using interstitial multicatheter brachytherapy. At 5-year follow-up, nine patients treated with APBI and five patients receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recurrence was 1.44% (95% CI 0.51-2.38) with APBI and 0.92% (0.12-1.73) with whole-breast irradiation (difference 0.52%, 95% CI -0.72 to 1.75; p=0.42). No grade 4 late side-effects were reported. The 5-year risk of grade 2-3 late side-effects to the skin was 3.2% with APBI versus 5.7% with whole-breast irradiation (p=0.08), and 5-year risk of grade 2-3 subcutaneous tissue late side-effects was 7.6% versus 6.3% (p=0.53). The risk of severe (grade 3) fibrosis at 5 years was 0.2% with whole-breast irradiation and 0% with APBI (p=0.46)., Interpretation: The difference between treatments was below the relevance margin of 3 percentage points. Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is not inferior to adjuvant whole-breast irradiation with respect to 5-year local control, disease-free survival, and overall survival., Funding: German Cancer Aid., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
22. Accelerated partial breast irradiation: the new standard?
- Author
-
Coles CE and Yarnold JR
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
23. Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.
- Author
-
Ahlawat S, Haffty BG, Goyal S, Kearney T, Kirstein L, Chen C, Moore DF, and Khan AJ
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Carcinoma in Situ pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular pathology, Disease-Free Survival, Female, Follow-Up Studies, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prospective Studies, Radiation Injuries pathology, Radiodermatitis pathology, Time Factors, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Lobular radiotherapy, Radiation Dose Hypofractionation
- Abstract
Purpose: Conventionally fractionated whole-breast irradiation (WBI) with a boost takes approximately 6 to 7 weeks. We evaluated a short course of hypofractionated (HF), accelerated WBI in which therapy was completed in 3 weeks inclusive of a sequential boost., Methods and Materials: We delivered a whole-breast dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days, followed by a lumpectomy bed boost in 4 fractions of 3.33 Gy delivered once daily for a total of 15 treatment days. Acute toxicities were scored using Common Terminology Criteria for Adverse Events version 4. Late toxicities were scored using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. Cosmesis was scored using the Harvard Cosmesis Scale. Our primary endpoint was freedom from locoregional failure; we incorporated early stopping criteria based on predefined toxicity thresholds. Cosmesis was examined as a secondary endpoint., Results: We enrolled 83 women with stages 0 to IIIa breast cancer. After a median follow-up of 40 months, 2 cases of isolated ipsilateral breast tumor recurrence occurred (2 of 83; crude rate, 2.4%). Three-year estimated local recurrence-free survival was 95.9% (95% confidence interval [CI]: 87.8%-98.7%). The 3-year estimated distant recurrence-free survival was 97.3% (95% CI: 89.8%-99.3%). Three-year secondary malignancy-free survival was 94.3% (95% CI: 85.3%-97.8%). Twenty-nine patients (34%) had grade 2 acute toxicity, and 1 patient had a late grade 2 toxicity (fibrosis). One patient had acute grade 3 dermatitis, whereas 2 patients experienced grade 3 late skin toxicity. Ninety-four percent of evaluable patients had good or excellent cosmesis., Conclusions: Our phase 2 institutional study offers one of the shortest courses of HF therapy, delivered in 15 fractions inclusive of a sequential boost. We demonstrated expected low toxicity and high local control rates with good to excellent cosmetic outcomes. This fractionation scheme is feasible and well tolerated and offers women WBI in a highly convenient schedule., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. [Risks of unfavorable cosmetic and toxicity after percutaneous accelerated partial breast irradiation (APBI). Interim analysis from the Canadian RAPID trial].
- Author
-
Piroth MD
- Subjects
- Female, Humans, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Radiotherapy, Adjuvant adverse effects, Radiotherapy, Adjuvant methods, Radiotherapy, Conformal adverse effects
- Published
- 2013
- Full Text
- View/download PDF
25. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
- Author
-
Goodwin A, Parker S, Ghersi D, and Wilcken N
- Subjects
- Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Combined Modality Therapy methods, Female, Humans, Mastectomy, Segmental, Radiotherapy adverse effects, Randomized Controlled Trials as Topic, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Background: The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer. Ductal carcinoma in situ (DCIS) is a pre-invasive lesion. Recurrence of ipsilateral disease following BCS can be either DCIS or invasive breast cancer. Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs., Objectives: To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms., Search Methods: We searched the Cochrane Breast Cancer Group Specialised Register (2 June 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 1), MEDLINE (2 June 2011), EMBASE (2 June 2011) and the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP; 2 June 2011). Reference lists of articles and handsearching of ASCO (2007), ESMO (2002 to 2007), and St Gallen (2005 to 2007) conferences were performed., Selection Criteria: RCTs of breast conserving surgery with and without radiotherapy in women at first diagnosis of pure ductal carcinoma in situ (no invasive disease present)., Data Collection and Analysis: Two authors independently assessed each potentially eligible trial for inclusion and its quality. Two authors also independently extracted data from published Kaplan-Meier analysis (survival curves) and reported summary statistics. Data were extracted and pooled for four trials. Data for planned subgroups were extracted and pooled for analysis.There were insufficient data to pool for long-term toxicity from radiotherapy., Main Results: Four RCTs involving 3925 women were identified and included in this review. All were high quality with minimal risk of bias. Three trials compared the addition of RT to BCS. One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm. Analysis confirmed a statistically significant benefit from the addition of radiotherapy on all ipsilateral breast events (hazards ratio (HR) 0.49; 95% CI 0.41 to 0.58, P < 0.00001), ipsilateral invasive recurrence (HR 0.50; 95% CI 0.32 to 0.76, p=0.001) and ipsilateral DCIS recurrence (HR 0.61; 95% CI 0.39 to 0.95, P = 0.03). All the subgroups analysed benefited from addition of radiotherapy. No significant long-term toxicity from radiotherapy was found. No information about short-term toxicity from radiotherapy or quality of life data were reported., Authors' Conclusions: This review confirms the benefit of adding radiotherapy to breast conserving surgery for the treatment of all women diagnosed with DCIS. No long-term toxicity from use of radiotherapy was identified.
- Published
- 2013
- Full Text
- View/download PDF
26. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy.
- Author
-
Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, and Julian JA
- Subjects
- Esthetics, Female, Humans, Middle Aged, Radiation Injuries epidemiology, Radiotherapy Planning, Computer-Assisted, Treatment Outcome, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Radiotherapy, Adjuvant adverse effects, Radiotherapy, Adjuvant methods, Radiotherapy, Conformal adverse effects
- Abstract
Purpose: To report interim cosmetic and toxicity results of a multicenter randomized trial comparing accelerated partial-breast irradiation (APBI) using three-dimensional conformal external beam radiation therapy (3D-CRT) with whole-breast irradiation (WBI)., Patients and Methods: Women age > 40 years with invasive or in situ breast cancer ≤ 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10 fractions twice daily) or WBI (42.5 Gy in 16 or 50 Gy in 25 daily fractions ± boost irradiation). The primary outcome was ipsilateral breast tumor recurrence (IBTR). Secondary outcomes were cosmesis and toxicity. Adverse cosmesis was defined as a fair or poor global cosmetic score. After a planned interim cosmetic analysis, the data, safety, and monitoring committee recommended release of results. There have been too few IBTR events to trigger an efficacy analysis., Results: Between 2006 and 2011, 2,135 women were randomly assigned to 3D-CRT APBI or WBI. Median follow-up was 36 months. Adverse cosmesis at 3 years was increased among those treated with APBI compared with WBI as assessed by trained nurses (29% v 17%; P < .001), by patients (26% v 18%; P = .0022), and by physicians reviewing digital photographs (35% v 17%; P < .001). Grade 3 toxicities were rare in both treatment arms (1.4% v 0%), but grade 1 and 2 toxicities were increased among those who received APBI compared with WBI (P < .001)., Conclusion: 3D-CRT APBI increased rates of adverse cosmesis and late radiation toxicity compared with standard WBI. Clinicians and patients are cautioned against the use of 3D-CRT APBI outside the context of a controlled trial.
- Published
- 2013
- Full Text
- View/download PDF
27. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.
- Author
-
Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, and Bijker N
- Subjects
- Adult, Breast Neoplasms mortality, Breast Neoplasms surgery, Carcinoma in Situ mortality, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast surgery, Combined Modality Therapy, Female, Humans, Kaplan-Meier Estimate, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local mortality, Proportional Hazards Models, Radiotherapy, Adjuvant, Treatment Outcome, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Purpose: Adjuvant radiotherapy (RT) after a local excision (LE) for ductal carcinoma in situ (DCIS) aims at reduction of the incidence of a local recurrence (LR). We analyzed the long-term risk on developing LR and its impact on survival after local treatment for DCIS., Patients and Methods: Between 1986 and 1996, 1,010 women with complete LE of DCIS less than 5 cm were randomly assigned to no further treatment (LE group, n = 503) or RT (LE+RT group, n = 507). The median follow-up time was 15.8 years., Results: Radiotherapy reduced the risk of any LR by 48% (hazard ratio [HR], 0.52; 95% CI, 0.40 to 0.68; P < .001). The 15-year LR-free rate was 69% in the LE group, which was increased to 82% in the LE+RT group. The 15-year invasive LR-free rate was 84% in the LE group and 90% in the LE+RT group (HR, 0.61; 95% CI, 0.42 to 0.87). The differences in LR in both arms did not lead to differences in breast cancer-specific survival (BCSS; HR, 1.07; 95% CI, 0.60 to 1.91) or overall survival (OS; HR, 1.02; 95% CI, 0.71 to 1.44). Patients with invasive LR had a significantly worse BCSS (HR, 17.66; 95% CI, 8.86 to 35.18) and OS (HR, 5.17; 95% CI, 3.09 to 8.66) compared with those who did not experience recurrence. A lower overall salvage mastectomy rate after LR was observed in the LE+RT group than in the LE group (13% v 19%, respectively)., Conclusion: At 15 years, almost one in three nonirradiated women developed an LR after LE for DCIS. RT reduced this risk by a factor of 2. Although women who developed an invasive recurrence had worse survival, the long-term prognosis was good and independent of the given treatment.
- Published
- 2013
- Full Text
- View/download PDF
28. Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost.
- Author
-
Chadha M, Woode R, Sillanpaa J, Lucido D, Boolbol SK, Kirstein L, Osborne MP, Feldman S, and Harrison LB
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ mortality, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Disease-Free Survival, Dose Fractionation, Radiation, Feasibility Studies, Female, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Staging, Prospective Studies, Skin radiation effects, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Purpose: To report early outcomes of accelerated whole-breast radiation therapy with concomitant boost., Methods and Materials: This is a prospective, institutional review board-approved study. Eligibility included stage TisN0, T1N0, and T2N0 breast cancer. Patients receiving adjuvant chemotherapy were ineligible. The whole breast received 40.5 Gy in 2.7-Gy fractions with a concomitant lumpectomy boost of 4.5 Gy in 0.3-Gy fractions. Total dose to the lumpectomy site was 45 Gy in 15 fractions over 19 days., Results: Between October 2004 and December 2010, 160 patients were treated; stage distribution was as follows: TisN0, n = 63; T1N0, n = 88; and T2N0, n = 9. With a median follow-up of 3.5 years (range, 1.5-7.8 years) the 5-year overall survival and disease-free survival rates were 90% (95% confidence interval [CI] 0.84-0.94) and 97% (95% CI 0.93-0.99), respectively. Five-year local relapse-free survival was 99% (95% CI 0.96-0.99). Acute National Cancer Institute/Common Toxicity Criteria grade 1 and 2 skin toxicity was observed in 70% and 5%, respectively. Among the patients with ≥ 2-year follow-up no toxicity higher than grade 2 on the Late Effects in Normal Tissues-Subjective, Objective, Management, and Analytic scale was observed. Review of the radiation therapy dose-volume histogram noted that ≥ 95% of the prescribed dose encompassed the lumpectomy target volume in >95% of plans. The median dose received by the heart D05 was 215 cGy, and median lung V20 was 7.6%., Conclusions: The prescribed accelerated schedule of whole-breast radiation therapy with concomitant boost can be administered, achieving acceptable dose distribution. With follow-up to date, the results are encouraging and suggest minimal side effects and excellent local control., (Copyright © 2013. Published by Elsevier Inc.)
- Published
- 2013
- Full Text
- View/download PDF
29. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.
- Author
-
Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Del Castillo A, Bassi F, Pagani G, DeCensi A, Viale G, Bonanni B, and Pruneri G
- Subjects
- Adult, Aged, Antineoplastic Agents, Hormonal administration & dosage, Breast Neoplasms metabolism, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ metabolism, Carcinoma in Situ radiotherapy, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast metabolism, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating metabolism, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery, Cohort Studies, Female, Humans, Immunohistochemistry, Middle Aged, Phenotype, Predictive Value of Tests, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Tamoxifen administration & dosage, Breast Neoplasms therapy, Carcinoma in Situ therapy, Carcinoma, Ductal, Breast therapy, Carcinoma, Intraductal, Noninfiltrating therapy, Ki-67 Antigen metabolism
- Abstract
Background: The post-surgical management of ductal intraepithelial neoplasia (DIN) of the breast is still a dilemma. Ki-67 labelling index (LI) has been proposed as an independent predictive and prognostic factor in early breast cancer., Methods: The prognostic and predictive roles of Ki-67 LI were evaluated with a multivariable Cox regression model in a cohort of 1171 consecutive patients operated for DIN in a single institution from 1997 to 2007., Results: Radiotherapy (RT) was protective in subjects with DIN with Ki-67 LI ≥ 14%, whereas no evidence of benefit was seen for Ki-67 LI <14%, irrespective of nuclear grade and presence of necrosis. Notably, the higher the Ki-67 LI, the stronger the effect of RT (P-interaction <0.01). Hormonal therapy (HT) was effective in both Luminal A (adjusted hazard ratio (HR)=0.56 (95% CI, 0.33-0.97)) and Luminal B/Her2neg DIN (HR 0.51 (95% CI, 0.27-0.95))., Conclusion: Our data suggest that Ki-67 LI may be a useful prognostic and predictive adjunct in DIN patients. The Ki-67 LI of 14% could be a potential cutoff for better categorising this population of women at increased risk for breast cancer and in which adjuvant treatment (RT, HT) should be differently addressed, independent of histological grade and presence of necrosis.
- Published
- 2013
- Full Text
- View/download PDF
30. [Breast-conserving surgery for ductal carcinoma in situ of the breast].
- Author
-
Shimada A
- Subjects
- Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Female, Humans, Radiotherapy, Adjuvant, Sentinel Lymph Node Biopsy, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Mastectomy, Segmental methods
- Published
- 2012
31. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age.
- Author
-
Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC, and Boughey JC
- Subjects
- Adult, Age Distribution, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms mortality, Breast Neoplasms pathology, Breast Neoplasms radiotherapy, Carcinoma in Situ mortality, Carcinoma in Situ pathology, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast radiotherapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Mastectomy, Segmental adverse effects, Middle Aged, Multivariate Analysis, Neoplasm Staging, Radiotherapy, Adjuvant, Risk Factors, Survival Analysis, Young Adult, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Mastectomy, Segmental statistics & numerical data, Neoplasm Recurrence, Local epidemiology
- Abstract
Background: Local recurrence (LR) after breast conservation surgery (BCS) varies with risk factors. This study was designed to evaluate the impact of young age on LR., Methods: All patients (excluding those who received neoadjuvant chemotherapy) who underwent BCS from 1988-2001 at our institution were identified and evaluated for risk factors of LR., Results: A total of 3,064 patients underwent 3,131 BCS. Mean age at surgery was 61 (range, 21-98) years: 175 (5.6%) patients were aged<40 years; 492 (15.7%) were 40-49 years; 761 (24.3%) were 50-59 years; 801 (25.6%) were 60-69 years; and 902 (28.8%) were age 70+years. A total of 212 patients (6.8%) developed LR at a mean of 4.5 (range, 0.1-14.4) years after BCS. Mean follow-up was 8.9 (range, 0-20.2) years. The 5-year LR-free survival rate was 94.9%. The frequencies of LR by age group were: <40 years--11.4%; 40-49 years--5.7%; 50-59 years--6.2%; 60-69 years--7.6%; 70 years and older--6.2%. The 5-year LR-free survival rates for these age groups were 90.5%, 95.4%, 95.5%, 95.4%, and 94.7%, respectively (P=0.09, log-rank test). On univariable analysis, patients aged<40 years were nearly twice as likely to experience LR (hazards ratio (HR), 1.81; P=0.012). Multivariable analysis of patients with complete data (n=2,122) demonstrated that age<40 years and node positivity were associated with increased risk of LR, whereas ER positivity and radiation therapy were associated with decreased risk., Conclusions: Risk factors for LR after BCS include age<40 years, node positivity, ER negativity, and absence of adjuvant radiation therapy. Patients younger than age 40 years are at increased risk of LR after BCS.
- Published
- 2012
- Full Text
- View/download PDF
32. Spinal cord stimulators and radiotherapy: first case report and practice guidelines.
- Author
-
Walsh L, Guha D, Purdie TG, Bedard P, Easson A, Liu FF, and Hodaie M
- Subjects
- Back Pain complications, Back Pain therapy, Combined Modality Therapy, Electrodes, Implanted, Female, Humans, Intervertebral Disc Displacement surgery, Lumbosacral Region, Mastectomy, Middle Aged, Neoplasm Grading, Neoplasm Staging, Neuralgia complications, Neuralgia therapy, Radiotherapy Planning, Computer-Assisted, Spinal Cord physiopathology, Spinal Fusion, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Electric Stimulation Therapy instrumentation, Radiotherapy, Adjuvant methods
- Abstract
Spinal cord stimulators (SCS) are a well-recognised treatment modality in the management of a number of chronic neuropathic pain conditions, particularly failed back syndrome and radiculopathies. The implantable pulse generator (IPG) component of the SCS is designed and operates in a similar fashion to that of a cardiac pacemaker. The IPG consists of an electrical generator, lithium battery, transmitter/receiver and a minicomputer. When stimulated, it generates pulsed electrical signals which stimulate the dorsal columns of the spinal cord, thus alleviating pain. Analogous to a cardiac pacemaker, it can be potentially damaged by ionising radiation from a linear accelerator, in patients undergoing radiotherapy. Herein we report our clinical management of the first reported case of a patient requiring adjuvant breast radiotherapy who had a SCS in situ. We also provide useful practical recommendations on the management of this scenario within a radiation oncology department.
- Published
- 2011
- Full Text
- View/download PDF
33. Outcomes after accelerated partial breast irradiation in patients with ASTRO consensus statement cautionary features.
- Author
-
McHaffie DR, Patel RR, Adkison JB, Das RK, Geye HM, and Cannon GM
- Subjects
- Age Factors, Brachytherapy standards, Breast Neoplasms mortality, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ mortality, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Consensus, Disease-Free Survival, Dose Fractionation, Radiation, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Patient Selection, Radiation Oncology standards, Risk, Societies, Medical standards, Tumor Burden, Wisconsin, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Purpose: To evaluate outcomes among women with American Society for Radiation Oncology (ASTRO) consensus statement cautionary features treated with brachytherapy-based accelerated partial breast irradiation (APBI)., Methods and Materials: Between March 2001 and June 2006, 322 consecutive patients were treated with high-dose-rate (HDR) APBI at the University of Wisconsin. A total of 136 patients were identified who met the ASTRO cautionary criteria. Thirty-eight (27.9%) patients possessed multiple cautionary factors. All patients received 32 to 34 Gy in 8 to 10 twice-daily fractions using multicatheter (93.4%) or Mammosite balloon (6.6%) brachytherapy., Results: With a median follow-up of 60 months, there were 5 ipsilateral breast tumor recurrences (IBTR), three local, and two loco-regional. The 5-year actuarial rate of IBTR was 4.8%±4.1%. The 5-year disease-free survival was 89.6%, with a cause-specific survival and overall survival of 97.6% and 95.3%, respectively. There were no IBTRs among 32 patients with ductal carcinoma in situ (DCIS) vs. 6.1% for patients with invasive carcinoma (p=0.24). Among 104 patients with Stage I or II invasive carcinoma, the IBTR rate for patients considered cautionary because of age alone was 0% vs. 12.7% in those deemed cautionary due to histopathologic factors (p=0.018)., Conclusions: Overall, we observed few local recurrences among patients with cautionary features. Women with DCIS and patients 50 to 59 years of age with Stage I/II disease who otherwise meet the criteria for suitability appear to be at a low risk of IBTR. Patients with tumor-related cautionary features will benefit from careful patient selection., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
34. Early stage breast cancer and radiotherapy: update.
- Author
-
Marta GN, Hanna SA, Martella E, Silva JL, and Carvalho Hde A
- Subjects
- Early Detection of Cancer, Female, Humans, Neoplasm Staging, Radiotherapy, Adjuvant methods, Randomized Controlled Trials as Topic, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Breast cancer (BC) is the most common malignancy among women. Therapeutic options are based on disease staging, histopathological characteristics, age, and others. The objective of the present study is to carry out an update of the concepts and definitions of radiotherapy (RT) in conservative treatment of early-stage breast cancer, with emphasis on indications, contraindications, RT dose fractionation schedules (classic, hypofractionated and partial breast irradiation), adjuvant RT in ductal carcinoma in situ (DCIS) and molecular predictors of recurrence. MEDLINE, SciELO and Cochrane databases were used for article selection. Adjuvant RT is indicated for patients with BC who underwent conservative breast surgery. In selected patients, hypofractionated or partial breast irradiation can be used. Adjuvant RT should be provided for all patients with DCIS. The correlation of RT and molecular predictors of local and systemic recurrence are not yet well-known.
- Published
- 2011
35. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
- Author
-
Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, and Fowble B
- Subjects
- Adult, Aged, Aged, 80 and over, Axilla, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Female, Humans, Lymph Node Excision methods, Mastectomy, Mastectomy, Segmental methods, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm, Residual, Radiotherapy, Adjuvant, Thoracic Wall, Tumor Burden, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Purpose: Resection margin status is one of the most significant factors for local recurrence in patients with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery with or without radiation. However, its impact on chest wall recurrence in patients treated with mastectomy is unknown. The purpose of this study was to determine chest wall recurrence rates in women with DCIS and close (<5 mm) or positive mastectomy margins in order to evaluate the potential role of radiation therapy., Methods and Materials: Between 1985 and 2005, 193 women underwent mastectomy for DCIS. Fifty-five patients had a close final margin, and 4 patients had a positive final margin. Axillary surgery was performed in 17 patients. Median follow-up was 8 years. Formal pathology review was conducted to measure and verify margin status. Nuclear grade, architectural pattern, and presence or absence of necrosis was recorded., Results: Median pathologic size of the DCIS in the mastectomy specimen was 4.5 cm. Twenty-two patients had DCIS of >5 cm or diffuse disease. Median width of the close final margin was 2 mm. Nineteen patients had margins of <1 mm. One of these 59 patients experienced a chest wall recurrence with regional adenopathy, followed by distant metastases 2 years following skin-sparing mastectomy. The DCIS was high-grade, 4 cm, with a 5-mm deep margin. A second patient developed an invasive cancer in the chest wall 20 years after her mastectomy for DCIS. This cancer was considered a new primary site arising in residual breast tissue., Conclusions: The risk of chest wall recurrence in this series of patients is 1.7% for all patients and 3.3% for high-grade DCIS. One out of 20 (5%) patients undergoing skin sparing or total skin-sparing mastectomy experienced a chest wall recurrence. This risk of a chest wall recurrence appears sufficiently low not to warrant a recommendation for postmastectomy radiation therapy for patients with margins of <5 mm. There were too few patients with positive margins to draw any firm conclusions., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
36. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.
- Author
-
Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD 3rd, Atherton PJ, Loprinzi CL, and Martenson JA
- Subjects
- Acute Disease, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Middle Aged, Mometasone Furoate, Pruritus drug therapy, Pruritus etiology, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Dermatologic Agents therapeutic use, Pregnadienediols therapeutic use, Radiodermatitis drug therapy
- Abstract
Purpose: A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy., Methods and Materials: Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply 0.1% MMF or placebo cream daily. The primary study endpoint was the provider-assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider-assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient-reported outcome measures included the Skindex-16, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality-of-life self-assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy., Results: A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider-assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for MMF vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient-reported outcome measures, the maximum Skindex-16 score for the MMF group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group's maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002)., Conclusion: Patients receiving daily MMF during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
37. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation.
- Author
-
Vicini F, Beitsch P, Quiet C, Gittleman M, Zannis V, Fine R, Whitworth P, Kuerer H, Haffty B, Keisch M, and Lyden M
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy adverse effects, Brachytherapy methods, Breast Neoplasms chemistry, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ chemistry, Carcinoma in Situ drug therapy, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast chemistry, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Esthetics, Female, Follow-Up Studies, Humans, Middle Aged, Radiotherapy Dosage, Receptors, Estrogen analysis, Registries, Treatment Outcome, Tumor Burden, Brachytherapy instrumentation, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Neoplasms, Second Primary pathology
- Abstract
Purpose: To present 5-year data on treatment efficacy, cosmetic results, and toxicities for patients enrolled on the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial., Methods and Materials: A total of 1440 patients (1449 cases) with early-stage breast cancer receiving breast-conserving therapy were treated with the MammoSite device to deliver accelerated partial-breast irradiation (APBI) (34 Gy in 3.4-Gy fractions). Of 1449 cases, 1255 (87%) had invasive breast cancer (IBC) (median size, 10 mm) and 194 (13%) had ductal carcinoma in situ (DCIS) (median size, 8 mm). Median follow-up was 54 months., Results: Thirty-seven cases (2.6%) developed an ipsilateral breast tumor recurrence (IBTR), for a 5-year actuarial rate of 3.80% (3.86% for IBC and 3.39% for DCIS). Negative estrogen receptor status (p=0.0011) was the only clinical, pathologic, or treatment-related variable associated with IBTR for patients with IBC and young age (<50 years; p=0.0096) and positive margin status (p=0.0126) in those with DCIS. The percentage of breasts with good/excellent cosmetic results at 60 months (n=371) was 90.6%. Symptomatic breast seromas were reported in 13.0% of cases, and 2.3% developed fat necrosis. A subset analysis of the first 400 consecutive cases enrolled was performed (352 with IBC, 48 DCIS). With a median follow-up of 60.5 months, the 5-year actuarial rate of IBTR was 3.04%., Conclusion: Treatment efficacy, cosmesis, and toxicity 5 years after treatment with APBI using the MammoSite device are good and similar to those reported with other forms of APBI with similar follow-up., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
38. Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ.
- Author
-
Wai ES, Lesperance ML, Alexander CS, Truong PT, Culp M, Moccia P, Lindquist JF, and Olivotto IA
- Subjects
- Aged, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Female, Humans, Mastectomy, Segmental, Middle Aged, Radiotherapy, Adjuvant, Recurrence, Treatment Outcome, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Dose Fractionation, Radiation, Radiotherapy methods
- Abstract
Background: Boost radiotherapy (RT) improves outcomes for patients with invasive breast cancer, but whether this is applicable to patients with pure ductal carcinoma in situ (DCIS) is unclear. This study examined outcomes from whole breast RT, with or without a boost, and the impact of different dose-fractionation schedules in a population-based cohort of women with pure DCIS treated with breast-conserving surgery (BCS)., Methods: Data was analyzed for 957 subjects diagnosed between 1985 and 1999. RT use was analyzed over time. Ten-year Kaplan-Meier local control (LC), breast cancer specific survival (BCSS), and overall survival (OS) were compared using the log-rank test. Cox regression modeling of LC was performed., Results: Median follow-up was 9.3 years. Of the patient cohort 475 (50%) had no RT (NoRT) after BCS, 338 (35%) had RT without a partial breast boost (RTNoB), and 144 (15%) had RT with boost (RT + B). Subjects with risk factors of local recurrence were more likely to receive RT. Subjects receiving adjuvant RT had a trend toward improved LC (15-year LC: NoRT 87%; RTNoB 94%; RT + B 91%; P = .065). Multivariable analysis showed that RT with or without a boost was significantly associated with improved LC (HR, 0.29 and 0.38, respectively, compared with NoRT, P = .025), with no difference associated with a boost or different dose-fractionation schedules., Conclusions: Adjuvant RT improves local control in patients with DCIS treated with BCS. Hypofractionation is as effective as standard fractionation schedules. Boost RT was not associated with improved LC compared with whole breast RT alone. Cancer 2011. © 2010 American Cancer Society., (Copyright © 2010 American Cancer Society.)
- Published
- 2011
- Full Text
- View/download PDF
39. Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk.
- Author
-
Tunon-de-Lara C, Lemanski C, Cohen-Solal-Le-Nir C, de Lafontan B, Charra-Brunaud C, Gonzague-Casabianca L, Mignotte H, Fondrinier E, Giard S, Quetin P, Auvray H, and Cutuli B
- Subjects
- Adult, Age Factors, Breast Neoplasms diagnosis, Breast Neoplasms radiotherapy, Carcinoma in Situ diagnosis, Carcinoma in Situ radiotherapy, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast diagnosis, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Disease-Free Survival, Female, Follow-Up Studies, France epidemiology, Humans, Kaplan-Meier Estimate, Mastectomy, Modified Radical, Mastectomy, Segmental, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local prevention & control, Patient Care Team, Predictive Value of Tests, Prognosis, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Breast Neoplasms epidemiology, Breast Neoplasms surgery, Carcinoma in Situ epidemiology, Carcinoma, Ductal, Breast epidemiology, Neoplasm Recurrence, Local epidemiology
- Abstract
Background: After breast conservative treatment (BCT), young age is a predictive factor for recurrence in patients with Ductal Carcinoma In Situ (DCIS) of the breast. The purpose of this study was to evaluate predictive factors for recurrence and outcomes in these younger women (under 40 years) treated for pure DCIS., Methods: From 1974 to 2003, 207 cases were collected in 12 French Cancer Centers. Median age was 36.3 years and median follow-up 160 months. Seventy four (35.8%) underwent mastectomy, 67 (32.4%) lumpectomy alone and 66 (31.9%) lumpectomy plus radiotherapy., Results: 37 recurrences occurred (17.8%): 14 (38%) were in situ and 23 (62%) invasive. After BCT, the overall rate of recurrence was 27% (33% in the lumpectomy plus radiotherapy group vs. 21% in the lumpectomy alone group). Comedocarcinoma subtype (p = 0.004), histological size more than 10 mm (p = 0.011), necrosis (p = 0.022) and positive margin status (p = 0.019) were statistically significant predictive factors for recurrence. The actuarial 15-year rates of local recurrence were 29%, 42% and 37% in the lumpectomy alone, lumpectomy and whole breast radiotherapy and lumpectomy + whole breast radiotherapy with additional boost groups respectively. After recurrence, the 10-year overall survival rate was 67.2%., Conclusion: High recurrence rates (mainly invasive) after BCT in young women with DCIS are confirmed. BCT in this subgroup of patients is possible if clear and large margins are obtained, tumor size is under 11 mm and necrosis- and/or comedocarcinoma-free., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
40. Improvement in interobserver accuracy in delineation of the lumpectomy cavity using fiducial markers.
- Author
-
Shaikh T, Chen T, Khan A, Yue NJ, Kearney T, Cohler A, Haffty BG, and Goyal S
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma in Situ radiotherapy, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Female, Humans, Middle Aged, Observer Variation, Prospective Studies, Radiotherapy, Conformal, Seroma pathology, Tomography, X-Ray Computed, Tumor Burden, Breast Neoplasms diagnostic imaging, Carcinoma in Situ diagnostic imaging, Carcinoma, Ductal, Breast diagnostic imaging, Gold, Mastectomy, Segmental, Prostheses and Implants, Seroma diagnostic imaging
- Abstract
Purpose: To determine, whether the presence of gold fiducial markers would improve the inter- and intraphysician accuracy in the delineation of the surgical cavity compared with a matched group of patients who did not receive gold fiducial markers in the setting of accelerated partial-breast irradiation (APBI)., Methods and Materials: Planning CT images of 22 lumpectomy cavities were reviewed in a cohort of 22 patients; 11 patients received four to six gold fiducial markers placed at the time of surgery. Three physicians categorized the seroma cavity according to cavity visualization score criteria and delineated each of the 22 seroma cavities and the clinical target volume. Distance between centers of mass, percentage overlap, and average surface distance for all patients were assessed., Results: The mean seroma volume was 36.9 cm(3) and 34.2 cm(3) for fiducial patients and non-fiducial patients, respectively (p = ns). Fiducial markers improved the mean cavity visualization score, to 3.6 ± 1.0 from 2.5 ± 1.3 (p < 0.05). The mean distance between centers of mass, average surface distance, and percentage overlap for the seroma and clinical target volume were significantly improved in the fiducial marker patients as compared with the non-fiducial marker patients (p < 0.001)., Conclusions: The placement of gold fiducial markers placed at the time of lumpectomy improves interphysician identification and delineation of the seroma cavity and clinical target volume. This has implications in radiotherapy treatment planning for accelerated partial-breast irradiation and for boost after whole-breast irradiation., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
41. Three-dimensional volumetric analysis of irradiated lung with adjuvant breast irradiation.
- Author
-
Teh AY, Park EJ, Shen L, and Chung HT
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Carcinoma in Situ pathology, Carcinoma, Ductal, Breast pathology, Female, Humans, Imaging, Three-Dimensional methods, Lung pathology, Middle Aged, Radiation Pneumonitis etiology, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy, Adjuvant, Retrospective Studies, Tomography, X-Ray Computed methods, Tumor Burden, Young Adult, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Lung radiation effects
- Abstract
Purpose: To retrospectively evaluate the dose-volume histogram data of irradiated lung in adjuvant breast radiotherapy (ABR) using a three-dimensional computed tomography (3D-CT)-guided planning technique; and to investigate the relationship between lung dose-volume data and traditionally used two-dimensional (2D) parameters, as well as their correlation with the incidence of steroid-requiring radiation pneumonitis (SRRP)., Methods and Materials: Patients beginning ABR between January 2005 and February 2006 were retrospectively reviewed. Patients included were women aged >or=18 years with ductal carcinoma in situ or Stage I-III invasive carcinoma, who received radiotherapy using a 3D-CT technique to the breast or chest wall (two-field radiotherapy [2FRT]) with or without supraclavicular irradiation (three-field radiotherapy [3FRT]), to 50 Gy in 25 fractions. A 10-Gy tumor-bed boost was allowed. Lung dose-volume histogram parameters (V(10), V(20), V(30), V(40)), 2D parameters (central lung depth [CLD], maximum lung depth [MLD], and lung length [LL]), and incidence of SRRP were reported., Results: A total of 89 patients met the inclusion criteria: 51 had 2FRT, and 38 had 3FRT. With 2FRT, mean ipsilateral V(10), V(20), V(30), V(40) and CLD, MLD, LL were 20%, 14%, 11%, and 8% and 2.0 cm, 2.1 cm, and 14.6 cm, respectively, with strong correlation between CLD and ipsilateral V(10-V40) (R(2) = 0.73-0.83, p < 0.0005). With 3FRT, mean ipsilateral V(10), V(20), V(30), and V(40) were 30%, 22%, 17%, and 11%, but its correlation with 2D parameters was poor. With a median follow-up of 14.5 months, 1 case of SRRP was identified., Conclusions: With only 1 case of SRRP observed, our study is limited in its ability to provide definitive guidance, but it does provide a starting point for acceptable lung irradiation during ABR. Further prospective studies are warranted.
- Published
- 2009
- Full Text
- View/download PDF
42. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
- Author
-
Goodwin A, Parker S, Ghersi D, and Wilcken N
- Subjects
- Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Combined Modality Therapy methods, Female, Humans, Mastectomy, Segmental, Radiotherapy adverse effects, Randomized Controlled Trials as Topic, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Background: The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer. Ductal carcinoma in situ (DCIS) is a pre-invasive lesion. Recurrence of ipsilateral disease following BCS can be either DCIS or invasive breast cancer. Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs., Objectives: To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms., Search Strategy: We searched the Cochrane Breast Cancer Group Specialised Register (January 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 1), MEDLINE (February 2008), and EMBASE (February 2008). Reference lists of articles and handsearching of ASCO (2007), ESMO (2002 to 2007), and St Gallen (2005 to 2007) conferences were performed., Selection Criteria: RCTs of breast conserving surgery with and without radiotherapy in women at first diagnosis of pure ductal carcinoma in situ (no invasive disease present)., Data Collection and Analysis: Two authors independently assessed each potentially eligible trial for inclusion and its quality. Two authors also independently extracted data from published Kaplan-Meier analysis (survival curves) and reported summary statistics. Data were extracted and pooled for four trials. Data for planned subgroups were extracted and pooled for analysis.There were insufficient data to pool for long-term toxicity from radiotherapy., Main Results: Four RCTs involving 3925 women were identified and included in this review. All were high quality with minimal risk of bias. Three trials compared the addition of RT to BCS. One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm. Analysis confirmed a statistically significant benefit from the addition of radiotherapy on all ipsilateral breast events (hazards ratio (HR) 0.49; 95% CI 0.41 to 0.58, P < 0.00001), ipsilateral invasive recurrence (HR 0.50; 95% CI 0.32 to 0.76, p=0.001) and ipsilateral DCIS recurrence (HR 0.61; 95% CI 0.39 to 0.95, P = 0.03). All the subgroups analysed benefited from addition of radiotherapy. No significant long-term toxicity from radiotherapy was found. No information about short-term toxicity from radiotherapy or quality of life data were reported., Authors' Conclusions: This review confirms the benefit of adding radiotherapy to breast conserving surgery for the treatment of all women diagnosed with DCIS. No long-term toxicity from use of radiotherapy was identified.
- Published
- 2009
- Full Text
- View/download PDF
43. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
- Author
-
Goodwin A, Parker S, Ghersi D, and Wilcken N
- Subjects
- Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Combined Modality Therapy methods, Female, Humans, Mastectomy, Segmental, Radiotherapy adverse effects, Randomized Controlled Trials as Topic, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Background: The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer. Ductal carcinoma in situ (DCIS) is a pre-invasive lesion. Recurrence of ipsilateral disease following BCS can be either DCIS or invasive breast cancer. Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs., Objectives: To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms., Search Strategy: We searched the Cochrane Breast Cancer Group Specialised Register (January 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 1), MEDLINE (February 2008), and EMBASE (February 2008). Reference lists of articles and handsearching of ASCO (2007), ESMO (2002 to 2007), and St Gallen (2005 to 2007) conferences were performed., Selection Criteria: RCTs of breast conserving surgery with and without radiotherapy in women at first diagnosis of pure ductal carcinoma in situ (no invasive disease present)., Data Collection and Analysis: Two authors independently assessed each potentially eligible trial for inclusion and its quality. Two authors also independently extracted data from published Kaplan-Meier analysis (survival curves) and reported summary statistics. Data were extracted and pooled for four trials. Data for planned subgroups were extracted and pooled for analysis.There were insufficient data to pool for long-term toxicity from radiotherapy., Main Results: Four RCTs involving 3925 women were identified and included in this review. All were high quality with minimal risk of bias. Three trials compared the addition of RT to BCS. One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm. Analysis confirmed a statistically significant benefit from the addition of radiotherapy on all ipsilateral breast events (hazards ratio (HR) 0.49; 95% CI 0.41 to 0.59, P < 0.00001) and ipsilateral DCIS recurrence (HR 0.64; 95% CI 0.41 to 1.01, P = 0.05). Pooled analysis for invasive recurrence did not reach statistical significance. All the subgroups analysed benefited from addition of radiotherapy. No significant long-term toxicity from radiotherapy was found. No information about short-term toxicity from radiotherapy or quality of life data were reported., Authors' Conclusions: This review confirms the benefit of adding radiotherapy to breast conserving surgery for the treatment of all women diagnosed with DCIS. No long-term toxicity from use of radiotherapy was identified.
- Published
- 2009
- Full Text
- View/download PDF
44. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials.
- Author
-
Goodwin A, Parker S, Ghersi D, and Wilcken N
- Subjects
- Aged, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Combined Modality Therapy methods, Female, Humans, Mastectomy, Segmental, Middle Aged, Odds Ratio, Postoperative Care methods, Prognosis, Radiotherapy, Adjuvant adverse effects, Randomized Controlled Trials as Topic, Treatment Outcome, Women's Health, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Radiotherapy, Adjuvant methods
- Abstract
Aim: To summarise the results of randomised trials testing the addition of radiotherapy (RT) to breast conserving surgery for ductal carcinoma in situ (DCIS); to determine whether there are subsets of women with DCIS who do not benefit from RT; and to determine what the balance may be between reduction in risk of recurrence and long-term toxicity., Methods: We performed a systematic review to resolve these questions, using standard Cochrane methodology to identify, select and appraise relevant randomised trials., Results: Four randomised controlled trials involving 3925 women were identified. All were high quality with minimal risk of bias. Analysis confirmed a statistically significant benefit from the addition of radiotherapy on all ipsilateral breast events (HR=0.49; 95% CI 0.41-0.58, p<0.00001). All subgroups analysed (margin status, age and grade) benefited from the addition of radiotherapy. Nine women require treatment with radiotherapy to prevent one ipsilateral breast recurrence (NNT=9). Deaths due to vascular disease, pulmonary toxicity and second cancers were low and not significantly higher for women who received radiotherapy., Concluding Statement: Radiotherapy was beneficial in all clinically relevant subgroups. Longer follow-up is required to detect any long-term toxicity from use of radiotherapy. To date, no increase in toxicity has been identified.
- Published
- 2009
- Full Text
- View/download PDF
45. Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.
- Author
-
Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, and Bonanni B
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Breast Neoplasms radiotherapy, Carcinoma in Situ pathology, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast radiotherapy, Cohort Studies, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Staging, Risk Factors, Treatment Outcome, Young Adult, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery
- Abstract
Introduction: Diagnosis of breast ductal intraepithelial neoplasia (DIN) has increased over the last decades, but proper postsurgical treatment remains controversial. We analyzed risk factors and treatment outcome in a large series of women treated at one institution., Methods: Women undergoing surgery for DIN at the European Institute of Oncology between 1996 and 2005, with follow-up until December 2006, were included., Results: We evaluated the postsurgical treatment outcome of 974 and 293 patients who underwent breast-conserving surgery (BCS) or mastectomy, respectively. The 5-year cumulative incidence of breast cancer (BC) events was 11.8%, with a significant trend according to age (from 43% in women <36 years to 8% in women >65 years). Among the 727 BCS patients with DIN2-DIN3 histology, 414 (57%) received radiotherapy (RT), and they were both younger and with worse prognostic factors than the 313 patients who did not receive it. In these groups, the adjusted hazard ratio (HR) for RT versus non-RT was 0.40 (95% confidence interval [CI], 0.26-0.63). Among the 691 BCS patients with estrogen receptor (ER)(+) disease, 329 (48%) received low-dose tamoxifen (either 5 mg/day or 20 mg once a week) and they were younger than the 362 who did not receive it. In these groups, the adjusted HR for tamoxifen versus no tamoxifen was 0.68 (95% CI, 0.43-1.07), and the HR was 0.55 (95% CI, 0.32-0.97) after excluding human epidermal growth factor receptor (HER)2/neu-overexpressing DIN., Conclusions: BC events were more frequent in young patients. RT was associated with a lower incidence of BC events. Low-dose tamoxifen was associated with a lower incidence of BC events in patients with ER(+) disease when HER-2 was not overexpressed. Further prospective studies should confirm our observations.
- Published
- 2009
- Full Text
- View/download PDF
46. Ductal carcinoma in situ of the breast in Israeli women treated by breast-conserving surgery followed by radiation therapy.
- Author
-
Jiveliouk I, Corn B, Inbar M, and Merimsky O
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Carcinoma in Situ mortality, Carcinoma, Ductal, Breast mortality, Chemotherapy, Adjuvant, Cohort Studies, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Israel, Mammography, Middle Aged, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Retrospective Studies, Survival Analysis, Treatment Outcome, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma in Situ radiotherapy, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Mastectomy, Segmental methods
- Abstract
Background: Lumpectomy followed by radiation therapy (RT) has become an accepted local management strategy for patients with small, mammographically detected ductal carcinoma in situ (DCIS) of the breast. The aim of this analysis is to describe control rates and patterns of relapse in a cohort of Israeli women with mammographically detected DCIS treated at a single medical center., Patients and Methods: The files of 107 consecutive patients with DCIS were retrieved from the cancer registry of the unit of RT. All women underwent lumpectomy followed by definitive RT, administered in conventional dose fractionation regimens. Oral tamoxifen, 20 mg/ day, was prescribed to all but 2 patients with positive receptors., Results: Within a median follow-up time of 52 months, no local recurrence of any breast tumor was found. There was no correlation between event-free survival and tumor size, focality, grading, hormone receptor status, administration of adjuvant hormonal therapy, timing of RT, and RT boost delivery. The 8-year overall survival, disease-free-survival, and event-free survival were 100, 100, and 87%, respectively., Conclusions: The results reported herein are consistent with short-term and intermediate-term outcomes that are better than the reported benchmarks from prospective randomized trials. Although this could reflect selection factors at a single institution, it is also plausible that a genetically distinct disease is present in this local population.
- Published
- 2009
- Full Text
- View/download PDF
47. [Skin-sparing mastectomy: an alternative to conventional mastectomy in breast cancer].
- Author
-
Ramos Boyero M
- Subjects
- Breast Implants, Breast Neoplasms drug therapy, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Ductal, Breast radiotherapy, Contraindications, Data Interpretation, Statistical, Esthetics, Female, Follow-Up Studies, Humans, Neoplasm Recurrence, Local surgery, Nipples, Radiotherapy, Adjuvant, Plastic Surgery Procedures, Retrospective Studies, Time Factors, Treatment Outcome, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Mastectomy, Subcutaneous methods
- Abstract
Women who require or desire mastectomy for breast cancer one option should be immediate breast reconstruction. Skin-sparing mastectomy (SSM) describes the surgery that maximises breast skin and infra- mammary fold preservation, significantly improves the symmetry and natural appearance and a more satisfied patient. In multiple studies, SSM seems to be oncologically safe in patients undergoing mastectomy for invasive T1-T2 tumours, multicentric tumours, ductal carcinoma in situ or risk-reduction. However, the technique should be avoided in patients with inflammatory breast cancer or in those with extensive tumour involvement of the skin. SSM with nipple areola complex preservation appears to be oncologically safe, providing that the tumour is not close to the nipple and the retro-areolar tissue is free of tumour. Though adjuvant radiotherapy is not an absolute contraindication to SSM, it should be used with caution since it decreases the final cosmetic result.
- Published
- 2008
- Full Text
- View/download PDF
48. Feasibility of accelerated whole-breast radiation in the treatment of patients with ductal carcinoma in situ of the breast.
- Author
-
Constantine C, Parhar P, Lymberis S, Fenton-Kerimian M, Han SC, Rosenstein BS, and Formenti SC
- Subjects
- Adult, Aged, Dose Fractionation, Radiation, Female, Humans, Middle Aged, Prospective Studies, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
Background: We report the results of a prospective trial investigating the use of accelerated, hypofractionated whole-breast radiation therapy after breast-conservation surgery for ductal carcinoma in situ (DCIS)., Patients and Methods: A total of 59 patients with a median age of 54 years (range, 36-78 years) completed a phase I/II study of hypofractionated radiation therapy for treatment of DCIS. Eligibility criteria included patients with mammographically detected DCIS, status after segmental mastectomy with negative margins, and no residual calcifications. All patients were treated with external-beam radiation therapy without a boost, over 3 weeks, to a total dose of 42 Gy to the entire breast (2.8 Gy per fraction in 15 fractions). To optimally spare heart and lung, 34 of the 59 patients (57%) were treated in the prone position. Twenty-nine of 59 patients (49%) received adjuvant hormonal therapy., Results: Overall, radiation therapy was well tolerated, with modest acute toxicity limited to grade 1 radiation dermatitis (76%), breast edema (17%), and fatigue (12%). With a median follow-up of 36 months, late toxicities included grade 1 hyperpigmentation changes (85%), induration (66%), asymmetry (64%), and breast fibrosis (17%), with 3 cases of grade 2 fibrosis and 1 case of grade 2 hyperpigmentation. Among the patients with >or= 3 years of follow-up, cosmesis was scored as good to excellent in 21 patients (91%) and fair in 2 patients (9%). At the time of this report, no ipsilateral or contralateral breast recurrences have occurred., Conclusion: These data demonstrate the feasibility of treating the whole breast for DCIS with a hypofractionated regimen, with modest acute and late toxicity.
- Published
- 2008
- Full Text
- View/download PDF
49. Effect of external boost volume in breast-conserving therapy on local control with long-term follow-up.
- Author
-
Jobsen JJ, van der Palen J, and Ong F
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Disease-Free Survival, Female, Follow-Up Studies, Humans, Mastectomy, Segmental, Middle Aged, Prospective Studies, Radiotherapy Dosage, Radiotherapy, Adjuvant, Regression Analysis, Tumor Burden, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Neoplasm Recurrence, Local prevention & control
- Abstract
Purpose: To determine the effects of boost volume (BV) in relation to margin status and tumor size on the development of local recurrence with breast-conserving therapy., Methods and Materials: Between 1983 and 1995, 1,073 patients with invasive breast cancer underwent 1,101 breast-conserving therapies. Of these 1,101 BCTs, 967 were eligible for analysis. The BV was categorized into tertiles: <66 cm(3) (n = 330), 66-98 cm(3) (n = 326), and >98 cm(3) (n = 311). The median follow-up was 141 months. Separate analyses were done for women < or =40 years and >40 years., Results: No significant difference in local recurrence was shown between the tertiles and the recurrence site. The 15-year local recurrence-free survival rate was 87.9% for the first tertile, 88.7% for the second, and 89% for the third. For women < or =40 years old, the corresponding 15-year local recurrence-free survival rate was 80%, 74.5%, and 69.2%. For women >40 years old, the corresponding rate was 88.7%, 89.5%, and 90.9%. At 5 years, women >40 years old had significantly more local failures in the first tertile; this difference disappeared with time. A test for trend showed significance at 5 years (p = 0.0105) for positive margins for ductal carcinoma in situ in women >40 years of age., Conclusion: The results of this study have shown that the size of the external BV has no major impact on local control. For women >40 years old, positive margins for ductal carcinoma in situ showed a trend with respect to BV at 5 years. The BV had no influence on local control in the case of positive margins for invasive carcinoma.
- Published
- 2008
- Full Text
- View/download PDF
50. [Ductal carcinoma in situ (DCIS): can radiotherapy be avoided?].
- Author
-
Coucke PA, Barthelemy N, Jansen N, Triviere N, and Jerusalem G
- Subjects
- Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast surgery, Female, Humans, Mastectomy, Neoplasm Recurrence, Local prevention & control, Randomized Controlled Trials as Topic, Risk Factors, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Abstract
There is a never ending discussion on the need for radiotherapy after conservative breast surgery for DCIS (Ductal Carcinoma In Situ). It is true that adjuvant irradiation does not yield any difference in overall survival in the published randomized trials. However, postoperative irradiation after breast conserving surgery (BCS) has been shown to significantly reduce ipsilateral breast event (IBE), whether this is a DCIS recurrence or a recurrence with an invasive component. The real question is to define if there is a subgroup of patients for whom radiotherapy can be withheld without taking any significant local risk. Nowadays, we are not able to define such a subgroup as the possible selection criteria to avoid radiotherapy have never been validated within a well designed prospective randomized trial. Therefore, we think that there is no available evidence to avoid radiotherapy after BCS for DCIS. However, radiotherapy is not indicated after mastectomy.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.